Results 201 to 210 of about 398,598 (315)

Does ischemic preconditioning really improve performance or it is just a placebo effect? [PDF]

open access: yesPLoS One, 2021
de Souza HLR   +4 more
europepmc   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

The Placebo Effect in Asthma

open access: green, 2014
Stefanie Dutile   +2 more
openalex   +1 more source

Editorial: Placebo and Nocebo Effects in Psychiatry and Beyond

open access: yesFrontiers in Psychiatry, 2020
Katja Weimer   +8 more
doaj   +1 more source

Placebo Effect of Caffeine on Physiological Parameters and Physical Performance. [PDF]

open access: yesNutrients
Ortiz-Sánchez D   +4 more
europepmc   +1 more source

Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Placebo effects are a significant challenge in the conduct of clinical trials. We explored how global recruitment patterns influence the extent of placebo responses in randomized controlled trials of psoriatic arthritis and plaque psoriasis.
Andreas Kerschbaumer   +8 more
wiley   +1 more source

When does the placebo effect have an impact on network meta-analysis results? [PDF]

open access: yesBMJ Evid Based Med
Nikolakopoulou A   +5 more
europepmc   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy